Treatment of Bleeding Gums with Unani Medicine Sunoon-e-Mukhrij-e-Rutubat.

Clinical Validation of Pharmacopoeal Formulation Sunoon-e-Mukhrij-e-Rutubat for symptomatic relief in Lissa-e-Damiya (Bleeding gums).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015447

Enrollment

240

Registered

2018-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K051- Chronic gingivitis Health Condition 2: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Sunoon-e-Mukhrij-e-Rutubat: 1 g Sunoon-e-Mukhrij-e-Rutubat Powder is Applied Local1y Twice daily. Massage gently on teeth and gums morning and bed time after meals. Control Interventi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group 18-65 years. 2. Patients having Lissa-e-Damiya (Bleeding gums) with or without any of the following symptoms: Painful chewing Waram al-Lissa (Gingival swelling) Humra al-Lissa (Gingival erythema) Dhahab Maâ?? al-Asnan (Sensitive teeth)

Exclusion criteria

Exclusion criteria: 1. Bleeding gums accompanied by impaired neurological functions (loss of balance, weakness, numbness, or speech disturbances), double vision, seizures, mental disturbances, and loss of consciousness. 2. Bleeding gums accompanied by persistent nausea, vomiting, fever and stiff neck. 3. Presence of a periodontal abscess as diagnosed from clinical examination of the bleeding gums. 4. Presence of concomitant bleeding due to any other condition such as soft-tissue lesions (e.g., aphthous/ traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis) or multiple hard-tissue (e.g., carious). 5. Known case of Hemophilia, Low platelet count (thrombocytopenia) and von Willebrand disease (VWD) etc. 6. History or clinical evidence of chronic diseases requiring long-term treatment, e.g., DM, hypertension, tuberculosis, HIV etc 7. Pregnant and lactating women. 8. History of Hypersensitivity to the study drug or any of its ingredients. 9. History of addiction (alcohol, drugs,tobacco)

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms ofLissa-e-Damiya (Bleeding Gums)Timepoint: 7 days	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: seven days	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026